Conditions: COPD
Keywords: COPD Indacatarol placebo crossover patient perception
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 40
Healthy volunteers: no

Brief summary:
This is a phase IV study of indacaterol 75 μg single-dose compared to placebo in moderate-severe COPD patients with breathing symptoms to assess time to patient's perception of onset of effect.

Detailed description:

Arms:
arm 1: In treatment 1: participants received indacaterol 75 µg one dose delivered via single-dose dry-powder inhaler (SDDPI) followed by treatment 2: placebo one dose via SDDPI between day 7 and 10. Albuterol was available for use as rescue medication. arm 2: In treatment 1, participants received placebo one dose delivered via SDDPI followed by treatment 2: indacaterol 75 µg one dose delivered via SDDPI between Day 7 and Day 10. Albuterol was available for use as rescue medication.

Interventions: intervention 1: indacaterol intervention 2: placebo
Intervention descriptions: intervention 1: delivered via single-dose dry-powder inhaler intervention 2: delivered via single-dose dry-powder inhaler

Protocol document: